Amicus Therapeutics is a renowned biopharmaceutical company based in New Jersey. The company went public in 2007. It was financed by various venture capital firms, including Canaan Partners, New Enterprise Associates and Radius Ventures. Amicus Therapeutics deals with rare and orphan diseases, primarily lysosomal storage disorders. They develop enzyme replacement therapies (ERRs) on the platform of Chaperon- Advanced Replacement Therapy (CHART). In 2014, Amicus Therapeutics stood out in the pharmaceutical industry when it was named “Broadest Portfolio of small molecules pharmacological chaperones.” The company’s first drug candidate is migalastat, a therapy used to stabilize endogenous mutant alpha-galactosidase in Fabry disease. Amicus Therapeutics also entered a three-year partnership with JCR Pharmaceutical and GlaxoSmithKline in the clinical trials of the co-formulation with recombinant alpha-galactosidase.
In 2008, Amicus Therapeutics expanded its operations to San Diego where they built a new research site. Michael J. Fox Foundation funded their research at UCLA, which was collaborated by David Geffen School of Medicine, with $500,000. Their pre-clinical partnership with Icahn School of Medicine in Mount Sinai also received $210,300 from the Alzheimer’s Drug Discovery Foundation in 2012 (https://finance.yahoo.com/quote/FOLD?ltr=1). The company acquired Callidus Biopharma in 2013, which helped them to expand their enzyme replacement therapy development for the treatment of Pompe disease. This was followed by the acquisition of Scioderm in 2015.
The company’s stable presence in the industry has been driven by its visionary leadership. John F. Crowley serves as CEO and chairman of the board. John’s transformative leadership is driven by his desire to deliver solutions to the orphan disease community (GoogleFinance). His mission is inspired by a first-hand experience where two of his children were diagnosed with Pompe disease in 1998. John holds a BS in Foreign Service and an MBA from the George Washington University and Harvard University respectively. He also holds a J.D from the University of Notre Dame Law School. Bradley L. Campbell is the president and COO of Amicus Therapeutics. He has over 15 years of experience in the orphan drug. Bradley has worked for top companies in the industry. He is a graduate of Duke University and Harvard University where he attained his B.A in Public Policy and earned his MBA respectively.